KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Autologous platelet rich plasma (A-PRP) combined with pelvic floor muscle training for the treatment of female stress urinary incontinence (SUI): A randomized control clinical trial.Neurourol UrodynPMID 38108468无 PMCID2024-Feb0.98未发现恶性肿瘤人群证据。待处理
Intrarectal injections of botulinum toxin versus placebo for the treatment of urge faecal incontinence in adults (FI-Toxin): a double-blind, multicentre, randomised, controlled phase 3 study.Lancet Gastroenterol HepatolPMID 38128556无 PMCID2024-Feb0.98未发现恶性肿瘤人群证据。待处理
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.Lancet OncolPMID 38134948无 PMCID2024-Feb1.00命中用户提供的消化道肿瘤阳性参考集。待处理
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.Lancet HIVPMID 38141637无 PMCID2024-Feb0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet HaematolPMID 38142695无 PMCID2024-Feb0.85The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result. However, it does not have a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) as required; the primary endpoint is a proportional outcome (incidence of CMV infection).待处理
Adaptive servo-ventilation for sleep-disordered breathing in patients with heart failure with reduced ejection fraction (ADVENT-HF): a multicentre, multinational, parallel-group, open-label, phase 3 randomised controlled trial.Lancet Respir MedPMID 38142697无 PMCID2024-Feb0.98未发现恶性肿瘤人群证据。待处理
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.Lancet OncolPMID 38142702无 PMCID2024-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.J NeurooncolPMID 38153582无 PMCID2024-Feb0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer with radiologically pure-solid appearance in Japan (JCOG0802/WJOG4607L): a post-hoc supplemental analysis of a multicentre, open-label, phase 3 trial.Lancet Respir MedPMID 38184010无 PMCID2024-Feb0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial.Mol Genet MetabPMID 38184428无 PMCID2024-Feb0.98未发现恶性肿瘤人群证据。待处理
Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies.Epilepsy BehavPMID 38184949无 PMCID2024-Feb0.98未发现恶性肿瘤人群证据。待处理
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.Lung CancerPMID 38198859无 PMCID2024-Feb0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Efficacy and Safety of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized, Clinical Trials.Clin TherPMID 38216351无 PMCID2024-Feb0.98未发现恶性肿瘤人群证据。待处理
Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES).Lung CancerPMID 38224653无 PMCID2024-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial.Lancet OncolPMID 38224701无 PMCID2024-Feb0.95The study meets most criteria (oncology, human, randomized, phase 3, drug intervention, original result) but the primary efficacy endpoint is complete control (a binary outcome at 120 hours), not a time-to-event endpoint like OS or PFS, and no Kaplan-Meier survival analysis or hazard ratio for a time-to-event outcome is reported.待处理
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Glob HealthPMID 38245116无 PMCID2024-Feb0.98未发现恶性肿瘤人群证据。待处理
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.Lancet HaematolPMID 38302221无 PMCID2024-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A psychosocial goal-setting and manualised support intervention for independence in dementia (NIDUS-Family) versus goal setting and routine care: a single-masked, phase 3, superiority, randomised controlled trial.Lancet Healthy LongevPMID 38310894PMC108343742024-Feb0.98未发现恶性肿瘤人群证据。待处理
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.Influenza Other Respir VirusesPMID 38314063PMC108377802024-Feb0.98未发现恶性肿瘤人群证据。待处理
PACE: randomized, controlled, multicentre, multinational, phase III study of PLX-PAD for critical limb ischaemia in patients unsuitable for revascularization: randomized clinical trial.Br J SurgPMID 38294084PMC108289252024-Jan-310.98未发现恶性肿瘤人群证据。待处理
The effects of synbiotic supplementation on blood pressure and other maternal outcomes in pregnant mothers with mild preeclampsia: a triple-blinded randomized controlled trial.BMC Womens HealthPMID 38297273PMC108292122024-Jan-310.98未发现恶性肿瘤人群证据。待处理
LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.BMC CancerPMID 38291372PMC108260802024-Jan-300.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.N Engl J MedPMID 38078508无 PMCID2024-Jan-250.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.N Engl J MedPMID 38084760无 PMCID2024-Jan-250.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Detailed statistical analysis plan for ALBINO: effect of Allopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome - a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III).TrialsPMID 38267942PMC108096132024-Jan-240.98未发现恶性肿瘤人群证据。待处理
Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA).Curr OncolPMID 38392042PMC108880262024-Jan-240.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.Br J DermatolPMID 37939793无 PMCID2024-Jan-230.98未发现恶性肿瘤人群证据。待处理
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.J Clin OncolPMID 37864337PMC108243892024-Jan-200.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.J Clin OncolPMID 37976444PMC108243712024-Jan-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.LancetPMID 38048786无 PMCID2024-Jan-200.85The trial is a Phase 3 randomized controlled trial with a drug intervention and reports a primary efficacy endpoint (8-week RBC-TI rate). However, the primary endpoint is a binary proportion, not a time-to-event (e.g., OS, PFS) measure analyzed via Kaplan-Meier or hazard ratio. The study also reports durable transfusion independence (approximately 1 year) in the interpretation, but the primary and key secondary analyses as presented in the abstract are based on binary rates and safety, not time-to-event endpoints with the required statistical methods. Therefore, it does not meet the specific 'time-to-event efficacy endpoint' criterion.待处理
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.N Engl J MedPMID 38231624PMC111561862024-Jan-180.98未发现恶性肿瘤人群证据。待处理
HBV-miR-3 is closely related to HBV replication and strongly predictive of HBeAg seroconversion in PegIFN-α treated patients.Sci RepPMID 38233602PMC107941942024-Jan-170.98未发现恶性肿瘤人群证据。待处理
Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study.Arthritis Res TherPMID 38233885PMC107928722024-Jan-170.98未发现恶性肿瘤人群证据。待处理
Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.TrialsPMID 38229199PMC107904972024-Jan-160.55This is a protocol paper for an ongoing phase 3 randomized trial in oncology with a time-to-event endpoint (PFS), but it does not report completed trial results. The drug intervention involves CAM2029 (octreotide subcutaneous depot) versus standard-of-care somatostatin receptor ligands (octreotide LAR or lanreotide), which are drugs, but the abstract does not provide efficacy results from the completed trial. It is not an original formal result report.待处理
Evaluation of the Efficacy and Safety of DW1903 in Patients with Gastritis: A Randomized, Double-Blind, Noninferiority, Multicenter, Phase 3 study.Gut LiverPMID 37309193PMC107914922024-Jan-150.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study.J Clin PsychiatryPMID 38236020无 PMCID2024-Jan-150.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.LancetPMID 38008109无 PMCID2024-Jan-130.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.LancetPMID 38104575无 PMCID2024-Jan-130.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.N Engl J MedPMID 38197816无 PMCID2024-Jan-110.98未发现恶性肿瘤人群证据。待处理
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial.J Clin OncolPMID 37788412无 PMCID2024-Jan-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.J Clin OncolPMID 37906724PMC108243732024-Jan-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).J Clin OncolPMID 37906726无 PMCID2024-Jan-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial.J Clin OncolPMID 38039427无 PMCID2024-Jan-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial.Antimicrob Agents ChemotherPMID 38095426PMC108693352024-Jan-100.98未发现恶性肿瘤人群证据。待处理
A phase III randomized controlled trial comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer: ARMADILLO trial (JCOG1904).Jpn J Clin OncolPMID 37801434无 PMCID2024-Jan-070.65This is a protocol for an ongoing Phase III randomized trial in oncology with a primary time-to-event endpoint, but it does not present results. The eligibility criteria require original formal-result reports of completed trials. Additionally, the drug intervention (specific chemotherapy agent(s)) is not explicitly detailed in the provided record, which is needed to confirm a drug-containing intervention.待处理
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.LancetPMID 38048793无 PMCID2024-Jan-060.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial).Neuro OncolPMID 37417948PMC107689942024-Jan-050.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial.Cancer Res CommunPMID 38059497PMC107657722024-Jan-040.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.Clin ChemPMID 38175595无 PMCID2024-Jan-040.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.JAMAPMID 38078870PMC107142842024-Jan-020.98未发现恶性肿瘤人群证据。待处理